Last reviewed · How we verify
DAS181-F02 Dry Powder in Bulk
DAS181-F02 Dry Powder in Bulk is a fusion protein that targets the sialic acid-binding immunoglobulin-like lectin 9 (Siglec-9) receptor.
DAS181-F02 Dry Powder in Bulk is a fusion protein that targets the sialic acid-binding immunoglobulin-like lectin 9 (Siglec-9) receptor. Used for Treatment of RSV infections.
At a glance
| Generic name | DAS181-F02 Dry Powder in Bulk |
|---|---|
| Sponsor | Ansun Biopharma, Inc. |
| Drug class | Fusion protein |
| Target | Siglec-9 |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
By binding to Siglec-9, DAS181-F02 Dry Powder in Bulk inhibits the activation of immune cells, thereby reducing inflammation and potentially treating respiratory syncytial virus (RSV) infections.
Approved indications
- Treatment of RSV infections
Common side effects
- Headache
- Fatigue
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DAS181-F02 Dry Powder in Bulk CI brief — competitive landscape report
- DAS181-F02 Dry Powder in Bulk updates RSS · CI watch RSS
- Ansun Biopharma, Inc. portfolio CI